vs
Five Point Holdings, LLC（FPH）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Five Point Holdings, LLC的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$13.6M vs $9.1M），Five Point Holdings, LLC净利率更高（-16.4% vs -60.3%，领先43.9%），Five Point Holdings, LLC同比增速更快（3.2% vs -49.9%），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -48.5%）
Five Point Holdings, LLC是美国头部房地产开发企业，主要在加利福尼亚州高需求市场打造大型总体规划综合社区，项目融合住宅、办公、零售、公共配套与休闲设施，为当地居民构建活力、可持续的宜居宜业环境。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FPH vs PLX — 直观对比
营收规模更大
FPH
是对方的1.5倍
$9.1M
营收增速更快
FPH
高出53.2%
-49.9%
净利率更高
FPH
高出43.9%
-60.3%
两年增速更快
PLX
近两年复合增速
-48.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $9.1M |
| 净利润 | $-2.2M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -43.5% | -51.1% |
| 净利率 | -16.4% | -60.3% |
| 营收同比 | 3.2% | -49.9% |
| 净利润同比 | -109.6% | -184.8% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FPHPLX
| Q1 26 | $13.6M | — | ||
| Q4 25 | $75.9M | $9.1M | ||
| Q3 25 | $13.5M | $17.9M | ||
| Q2 25 | $7.5M | $15.7M | ||
| Q1 25 | $13.2M | $10.1M | ||
| Q4 24 | $159.8M | $18.2M | ||
| Q3 24 | $17.0M | $18.0M | ||
| Q2 24 | $51.2M | $13.5M |
净利润FPHPLX
| Q1 26 | $-2.2M | — | ||
| Q4 25 | $58.7M | $-5.5M | ||
| Q3 25 | $21.1M | $2.4M | ||
| Q2 25 | $3.3M | $164.0K | ||
| Q1 25 | $23.3M | $-3.6M | ||
| Q4 24 | $121.0M | $6.5M | ||
| Q3 24 | $4.8M | $3.2M | ||
| Q2 24 | $14.7M | $-2.2M |
毛利率FPHPLX
| Q1 26 | — | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% |
营业利润率FPHPLX
| Q1 26 | -43.5% | — | ||
| Q4 25 | 89.0% | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | 87.5% | 39.6% | ||
| Q3 24 | 83.6% | 22.2% | ||
| Q2 24 | 86.1% | -18.0% |
净利率FPHPLX
| Q1 26 | -16.4% | — | ||
| Q4 25 | 77.3% | -60.3% | ||
| Q3 25 | 156.2% | 13.2% | ||
| Q2 25 | 44.4% | 1.0% | ||
| Q1 25 | 177.0% | -35.8% | ||
| Q4 24 | 75.7% | 35.6% | ||
| Q3 24 | 28.0% | 18.0% | ||
| Q2 24 | 28.8% | -16.4% |
每股收益（稀释后）FPHPLX
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $332.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $48.2M |
| 总资产 | $3.2B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FPHPLX
| Q1 26 | $332.6M | — | ||
| Q4 25 | $425.5M | $14.7M | ||
| Q3 25 | $351.1M | $13.6M | ||
| Q2 25 | $456.6M | $17.9M | ||
| Q1 25 | $528.3M | $19.5M | ||
| Q4 24 | $430.9M | $19.8M | ||
| Q3 24 | $224.5M | $27.4M | ||
| Q2 24 | $217.4M | $23.4M |
股东权益FPHPLX
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $48.2M | ||
| Q3 25 | $2.3B | $52.9M | ||
| Q2 25 | $2.2B | $49.9M | ||
| Q1 25 | $2.2B | $45.2M | ||
| Q4 24 | $2.2B | $43.2M | ||
| Q3 24 | $2.0B | $32.4M | ||
| Q2 24 | $2.0B | $28.6M |
总资产FPHPLX
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $82.3M | ||
| Q3 25 | $3.2B | $82.3M | ||
| Q2 25 | $3.2B | $78.5M | ||
| Q1 25 | $3.2B | $73.9M | ||
| Q4 24 | $3.1B | $73.4M | ||
| Q3 24 | $2.9B | $61.6M | ||
| Q2 24 | $2.9B | $91.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-44.5M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FPHPLX
| Q1 26 | $-44.5M | — | ||
| Q4 25 | $105.2M | $2.0M | ||
| Q3 25 | $40.4M | $-3.7M | ||
| Q2 25 | $-71.6M | $-5.2M | ||
| Q1 25 | $56.7M | $-5.1M | ||
| Q4 24 | $116.0M | $4.0M | ||
| Q3 24 | $-18.0M | $4.1M | ||
| Q2 24 | $-23.2M | $-3.6M |
自由现金流FPHPLX
| Q1 26 | — | — | ||
| Q4 25 | $105.0M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-71.7M | $-5.7M | ||
| Q1 25 | $56.7M | $-5.4M | ||
| Q4 24 | $115.2M | $3.6M | ||
| Q3 24 | $-18.2M | $4.0M | ||
| Q2 24 | $-23.6M | $-3.8M |
自由现金流率FPHPLX
| Q1 26 | — | — | ||
| Q4 25 | 138.4% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -959.3% | -36.2% | ||
| Q1 25 | 430.9% | -53.0% | ||
| Q4 24 | 72.1% | 19.6% | ||
| Q3 24 | -106.9% | 22.4% | ||
| Q2 24 | -46.1% | -28.1% |
资本支出强度FPHPLX
| Q1 26 | 0.0% | — | ||
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.8% | 2.8% | ||
| Q1 25 | 0.3% | 3.0% | ||
| Q4 24 | 0.5% | 2.3% | ||
| Q3 24 | 1.3% | 0.5% | ||
| Q2 24 | 0.7% | 1.3% |
现金转化率FPHPLX
| Q1 26 | — | — | ||
| Q4 25 | 1.79× | — | ||
| Q3 25 | 1.92× | -1.58× | ||
| Q2 25 | -21.58× | -31.91× | ||
| Q1 25 | 2.44× | — | ||
| Q4 24 | 0.96× | 0.61× | ||
| Q3 24 | -3.77× | 1.27× | ||
| Q2 24 | -1.58× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FPH
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
